OPKO Health, Inc
(NASDAQ:OPK)

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the de...

Website: http://www.opko.com

Founded: 1991

Full Time Employees: 6,096

CEO: Phillip Frost

Sector: Healthcare

Industry: Diagnostics & Research

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31

revenues:
revenue from services	72,186,000	71,085,000	95,244,000	101,101,000	102,844,000	103,110,000	121,271,000	129,395,000	126,890,000	124,175,000	131,679,000	127,052,000	132,368,000	139,371,000	142,856,000	186,804,000	286,599,000	362,794,000	340,163,000	397,197,000	506,951,000	457,933,000	382,498,000	250,971,000	170,839,000	177,946,000	181,139,000	178,458,000	178,891,000	183,068,000	202,811,000	216,055,000	211,315,000	148,084,000	229,035,000	256,671,000	255,286,000	234,570,000	259,025,000	266,012,000	252,522,000	221,810,000	103,919,000	1,908,000	2,069,000	2,060,000	2,482,000	2,153,000	1,970,000	2,608,000	2,770,000	3,188,000	3,092,000
revenue from products	38,042,000	43,663,000	37,676,000	40,743,000	34,842,000	37,436,000	39,143,000	40,485,000	38,047,000	43,004,000	40,670,000	43,500,000	40,383,000	37,907,000	32,388,000	35,892,000	36,658,000	35,280,000	36,882,000	35,663,000	33,945,000	30,819,000	28,702,000	29,356,000	31,074,000	32,041,000	26,161,000	28,680,000	25,301,000	25,343,000	25,395,000	28,523,000	27,851,000	33,767,000	22,795,000	28,966,000	22,231,000	20,192,000	20,569,000	22,807,000	19,899,000	21,080,000	20,765,000
revenue from transfer of intellectual property and other	13,968,000	33,702,000	18,749,000	14,963,000	12,266,000	43,092,000	13,218,000	12,306,000	8,749,000	14,725,000	6,246,000	94,866,000	64,826,000	8,062,000	4,500,000	87,197,000	5,962,000	3,257,000	8,768,000	9,548,000	4,269,000	5,922,000	16,864,000	20,880,000	9,553,000	14,356,000	21,472,000	19,230,000	18,259,000	13,443,000	21,609,000	19,107,000	15,748,000	11,849,000	11,665,000	28,576,000	18,579,000	20,727,000	18,441,000	68,281,000	18,616,000
total revenues	124,196,000	148,450,000	151,669,000	156,807,000	149,952,000	183,638,000	173,632,000	182,186,000	173,686,000	181,904,000	178,595,000	265,418,000	237,577,000	185,340,000	179,744,000	309,893,000	329,219,000	401,331,000	385,813,000	442,408,000	545,165,000	494,674,000	428,064,000	301,207,000	211,466,000	224,343,000	228,772,000	226,368,000	222,451,000	221,854,000	249,815,000	263,685,000	254,914,000	193,700,000	263,495,000	314,213,000	296,096,000	275,489,000	298,035,000	357,100,000	291,037,000	276,191,000	143,034,000	42,429,000	30,084,000	25,533,000	19,773,000	23,545,000	22,274,000	20,692,000	20,641,000	23,821,000	31,376,000	16,261,000	11,795,000
yoy	-17.18%	-19.16%	-12.65%	-13.93%	-13.66%	0.95%	-2.78%	-31.36%	-26.89%	-1.85%	-0.64%	-14.35%	-27.84%	-53.82%	-53.41%	-29.95%	-39.61%	-18.87%	-9.87%	46.88%	157.80%	120.50%	87.11%	33.06%	-4.94%	1.12%	-8.42%	-14.15%	-12.73%	14.53%	-5.19%	-16.08%	-13.91%	-29.69%	-11.59%	-12.01%	1.74%	-0.25%	108.37%	741.64%	867.41%	981.70%	623.38%	80.20%	35.06%	23.40%	-4.21%	-1.16%	-29.01%	27.25%	75.00%
qoq	-16.34%	-2.12%	-3.28%	4.57%	-18.34%	5.76%	-4.70%	4.89%	-4.52%	1.85%	-32.71%	11.72%	28.18%	3.11%	-42.00%	-5.87%	-17.97%	4.02%	-12.79%	-18.85%	10.21%	15.56%	42.12%	42.44%	-5.74%	-1.94%	1.06%	1.76%	0.27%	-11.19%	-5.26%	3.44%	31.60%	-26.49%	-16.14%	6.12%	7.48%	-7.56%	-16.54%	22.70%	5.38%	93.09%	237.11%	41.04%	17.82%	29.13%	-16.02%	5.71%	7.65%	0.25%	-13.35%	-24.08%	92.95%	37.86%
costs and expenses:
cost of service revenue	56,143,000	60,047,000	80,402,000	82,383,000	84,518,000	76,311,000	108,847,000	107,078,000	109,873,000	112,370,000	106,375,000	113,028,000	114,059,000	106,327,000	128,182,000	171,836,000	221,202,000	271,744,000	223,193,000	267,807,000	339,429,000	300,926,000	255,292,000	144,794,000	122,887,000	124,877,000	126,348,000	130,078,000	129,903,000	135,458,000	137,347,000	134,408,000	139,441,000	139,883,000	135,203,000	143,901,000	139,966,000	146,982,000	138,554,000	140,971,000	137,597,000	15,358,500	56,670,000
cost of product revenue	22,298,000	24,378,000	21,374,000	25,022,000	22,814,000	22,668,000	24,656,000	23,455,000	21,744,000	24,827,000	24,543,000	25,911,000	24,255,000	23,019,000	20,263,000	22,475,000	22,673,000	21,079,000	20,764,000	25,101,000	24,078,000	17,799,000	17,481,000	17,857,000	17,371,000	17,404,000	15,573,000	14,145,000	14,156,000	14,073,000	13,609,000	15,652,000	14,648,000	16,736,000	16,107,000	13,505,000	14,830,000	12,346,000	12,626,000	12,468,000	9,939,000	11,284,000	10,658,000
selling, general and administrative	48,607,000	50,515,000	53,804,000	59,597,000	59,086,000	67,029,000	98,203,000	68,821,000	70,167,000	72,883,000	72,240,000	79,794,000	75,642,000	73,997,000	79,674,000	101,464,000	117,537,000	138,214,000	105,120,000	113,236,000	112,286,000	101,824,000	99,897,000	77,721,000	76,132,000	79,130,000	80,542,000	88,475,000	95,158,000	95,104,000	84,071,000	87,653,000	91,519,000	124,635,000	131,336,000	128,338,000	136,685,000	120,530,000	124,845,000	117,511,000	128,001,000	102,947,000	55,246,000	20,937,000	17,446,000	15,243,000	14,010,000	14,874,000	13,812,000	15,445,000	13,572,000	13,879,000	12,424,000	10,367,000	7,322,000	5,435,000	4,671,000	5,067,000	4,348,000	4,919,000	5,586,000
research and development	29,199,000	32,772,000	30,078,000	30,342,000	30,841,000	30,425,000	28,770,000	24,082,000	21,937,000	19,394,000	19,435,000	18,159,000	32,605,000	19,528,000	18,792,000	17,254,000	18,312,000	21,007,000	18,306,000	18,222,000	19,315,000	17,454,000	18,493,000	17,608,000	21,760,000	23,038,000	30,017,000	28,286,000	36,529,000	33,328,000	30,160,000	29,211,000	32,887,000	34,242,000	32,329,000	32,593,000	26,022,000	27,611,000	24,424,000	31,348,000	27,822,000	25,478,000	18,937,000	29,570,000	25,503,000	25,827,000	20,517,000	16,234,000	20,994,000	23,350,000	11,085,000	9,557,000	9,910,000	6,578,000	3,621,000	4,490,000	4,831,000	4,255,000	3,301,000	3,154,000	1,645,000
amortization of intangible assets	18,966,000	19,055,000	19,531,000	19,444,000	19,861,000	20,344,000	20,433,000	20,420,000	21,437,000	21,489,000	21,534,000	21,535,000	21,474,000	21,559,000	21,407,000	22,793,000	22,025,000	12,518,000	12,609,000	12,574,000	12,577,000	12,638,000	13,879,000	14,937,000	14,938,000	15,390,000	16,412,000	16,419,000	16,562,000	16,536,000	16,899,000	17,227,000	17,271,000	30,774,000	18,023,000	17,953,000	17,929,000	17,070,000	18,116,000	15,778,000	13,443,000	13,966,000	8,110,000	3,236,000	2,665,000	2,615,000	2,735,000	2,826,000	2,744,000	2,941,000	2,790,000	2,688,000	2,714,000
total costs and expenses	175,213,000	186,767,000	103,613,000	216,788,000	217,120,000	216,777,000	159,416,000	243,856,000	245,158,000	250,950,000	243,002,000	258,393,000	268,171,000	240,609,000	267,564,000	320,632,000	401,643,000	464,415,000	347,987,000	436,837,000	506,728,000	445,318,000	406,125,000	274,028,000	252,228,000	336,807,000	267,783,000	273,628,000	297,769,000	311,867,000	283,279,000	268,793,000	297,525,000	347,322,000	321,785,000	340,656,000	337,803,000	325,889,000	321,658,000	328,834,000	318,555,000	284,125,000	151,257,000	67,838,000	86,998,000	57,987,000	67,974,000	58,430,000	52,551,000	56,558,000	39,651,000	41,804,000
operating income	-51,017,000	-38,317,000	48,056,000	-59,981,000	-67,168,000	-33,139,000	14,216,000	-61,670,000	-71,472,000	-69,046,000	-64,407,000	7,025,000	-30,594,000	-55,269,000	-87,820,000	-10,739,000	-72,424,000	-63,084,000	37,826,000	5,571,000	38,437,000	49,356,000	21,939,000	27,179,000	-40,762,000	-112,464,000	-39,011,000	-47,260,000	-75,318,000	-90,013,000	-33,464,000	-5,108,000	-42,611,000	-153,622,000	-58,290,000	-26,443,000	-41,707,000	-50,400,000	-23,623,000	28,266,000	-27,518,000	-7,934,000	-8,223,000	-25,409,000	-56,914,000	-32,454,000	-48,201,000	-34,885,000	-30,277,000											-5,162,000	-5,086,000
yoy	-24.05%	15.63%	238.04%	-2.74%	-6.02%	-52.00%	-122.07%	-977.86%	133.61%	24.93%	-26.66%	-165.42%	-57.76%	-12.39%	-332.17%	-292.77%	-288.42%	-227.81%	72.41%	-79.50%	-194.30%	-143.89%	-156.24%	-157.51%	-45.88%	24.94%	16.58%	825.22%	76.76%	-41.41%	-42.59%	-80.68%	2.17%	204.81%	146.75%	-193.55%	51.56%	535.24%	187.28%	-211.24%	-51.65%	-75.55%	-82.94%	-27.16%	87.98%
qoq	33.14%	-179.73%	-180.12%	-10.70%	102.69%	-333.11%	-123.05%	-13.71%	3.51%	7.20%	-1016.83%	-122.96%	-44.65%	-37.07%	717.77%	-85.17%	14.81%	-266.77%	578.98%	-85.51%	-22.12%	124.97%	-19.28%	-166.68%	-63.76%	188.29%	-17.45%	-37.25%	-16.33%	168.98%	555.13%	-88.01%	-72.26%	163.55%	120.44%	-36.60%	-17.25%	113.35%	-183.57%	-202.72%	246.84%	-3.51%	-67.64%	-55.36%	75.37%	-32.67%	38.17%	15.22%												1.49%
operating margin %	-41.08%	-25.81%	31.68%	-38.25%	-44.79%	-18.05%	8.19%	-33.85%	-41.15%	-37.96%	-36.06%	2.65%	-12.88%	-29.82%	-48.86%	-3.47%	-22.00%	-15.72%	9.80%	1.26%	7.05%	9.98%	5.13%	9.02%	-19.28%	-50.13%	-17.05%	-20.88%	-33.86%	-40.57%	-13.40%	-1.94%	-16.72%	-79.31%	-22.12%	-8.42%	-14.09%	-18.29%	-7.93%	7.92%	-9.46%	-2.87%	-5.75%	-59.89%	-189.18%	-127.11%	-243.77%	-148.16%	-135.93%	0%	0%	0%	0%	0%	0%	NaN%	NaN%	NaN%	NaN%	-Infinity%	-Infinity%
other income, net:
interest income	3,007,000	3,820,000	3,023,000	3,287,000	4,681,000	4,294,000	2,928,000	391,000	813,000	906,000	970,000	1,077,000	1,030,000	1,143,000	667,000	161,000	10,000	7,000	9,000	6,000	5,000	3,000	1,000	5,000	142,000	233,000	350,000	572,000	556,000	1,129,000	43,000	27,000	39,000	-24,000	249,000	136,000	249,000	137,000	163,000	135,000	43,000	228,000	13,000	5,000	8,000	321,000	402,000	7,000	40,000	139,000	88,000	90,000	59,000	65,000	49,000	47,000	27,000
interest expense	-10,939,000	-11,310,000	-11,358,000	-70,327,000	-15,466,000	-14,240,000	-17,359,000	-8,180,000	-7,686,000	-3,453,000	-3,384,000	-3,277,000	-3,391,000	-3,302,000	-3,017,000	-3,075,000	-2,662,000	-4,308,000	-4,290,000	-4,887,000	-5,395,000	-5,420,000	-5,544,000	-5,474,000	-5,496,000	-5,468,000	-5,792,000	-5,501,000	-4,755,000	-3,957,000	-2,944,000	-2,722,000	-2,267,000	-1,830,000	-1,840,000	-1,502,000	-1,429,000	-1,408,000	-2,018,000	-2,217,000	-1,787,000	-2,123,000	-2,745,000	-986,000	-2,565,000	-1,691,000	-2,402,000	-4,685,000	-3,486,000	-3,654,000	-3,409,000	-3,842,000	-2,897,000	-430,000	-393,000	-231,000	-351,000
fair value changes of derivative instruments	-298,000	-134,000	-38,000	16,000	-273,000		-1,000	1,000	-26,161,000	48,000	88,000	142,000	-1,059,000	-3,000	446,000	338,000	-132,000	275,000	1,283,000	-272,000	-439,000	-62,000	-496,000	-13,000	621,000	168,000	-21,000	-388,000	415,000	-446,000	-155,000	2,248,000	1,396,000	-1,917,000	-7,550,000	5,482,000	4,037,000	8,667,000	-5,701,000	1,235,000	-1,423,000	-4,983,000	32,244,000	-16,556,000	-49,788,000	-14,390,000	3,305,000	10,967,000	-10,515,000	2,202,000	-27,793,000	12,651,000	-23,549,000
other income	-1,709,000	-960,000	1,748,000	-35,515,000	4,852,000	78,069,000	48,636,000	58,874,000	21,323,000			-21,417,000	17,017,000				-1,442,000	1,297,000	-3,356,000	-11,783,000	-927,000	2,064,000	4,749,000	18,223,000	-12,332,000	9,086,000	-15,470,000	-5,874,000	977,000	-8,118,000	-824,000	8,584,000	1,893,000	7,352,000	597,000	-533,000	3,042,000	360,000	-2,972,000	5,970,000	546,000	-9,004,000	17,482,000	760,000	-1,508,000	-5,132,000	-2,764,000	2,990,000	1,817,000	22,758,000	-7,787,000	8,027,000	2,331,000	-6,000	224,000	-243,000	1,298,000				38,000
other expense	-9,939,000				-6,206,000					-11,253,000	-11,645,000			-27,772,750	-36,651,000	-72,997,000																																										430,000	-671,000	-139,000
loss before income taxes and investment losses	-60,956,000			-162,520,000	-73,374,000			-10,584,000	-83,183,000	-72,494,000	-78,378,000	-16,450,000	-16,997,000												-57,827,000	-108,445,000	-59,944,000		-78,125,000	-101,405,000	-37,344,000		-41,550,000	-150,041,000	-66,834,000		-35,808,000				-30,139,000			-42,186,000	-110,767,000	-53,346,000	-49,660,000	-25,606,000	-42,421,000			-1,057,000	-30,829,000								-5,048,000
income tax benefit	6,110,000	15,661,000	-19,797,000	14,079,000	5,770,000			280,000	1,350,000	6,019,000	-6,075,000	-3,148,000	-1,233,000	16,975,000	40,327,000	-15,070,000	21,266,000	-1,998,250	-2,680,000			-13,596,000	3,178,000			-3,424,000	-1,769,000		-783,000	28,289,000	11,563,000	-2,017,000	892,000	-61,164,000	24,405,000	10,960,000	6,944,000	31,489,000	19,988,000	-15,868,000	20,506,000	26,457,000	92,978,000	-251,000	-5,509,000				-614,000
net loss before investment losses	-54,846,000			-148,441,000	-67,604,000			-10,304,000	-81,833,000	-66,475,000	-84,453,000	-19,598,000	-18,230,000												-58,998,000	-111,869,000	-61,713,000		-78,908,000	-73,116,000	-25,781,000		-40,658,000	-211,205,000	-42,429,000		-28,864,000
loss from investments in investees	-2,000	-17,000	-3,000		-9,000	-11,000	-3,000	-1,000	-3,000	-8,000	-20,000	-42,000	-37,000	-24,000	-43,000	-268,000	-49,000	-466,000	-53,000	-67,000	-43,000	-47,000	-110,000	-189,000	-134,000	-481,000	-294,000	-271,000	-1,854,000	-2,955,000	-1,874,000	-7,213,000	-2,456,000	-2,700,000	-4,013,000	-5,628,000	-2,131,000	-2,505,000	-814,000	-1,988,000	-2,345,000	-1,038,000	-3,502,000	-804,000	-1,761,000	-1,101,000	-60,000	-370,000	-2,056,000	-3,595,000	-1,600,000	-2,371,000	-3,890,000	-598,000	-468,000	-475,000	-523,000	-414,000	-301,000	-451,000	-423,000
net income	-54,848,000	-31,257,000	21,631,000	-148,441,000	-67,613,000	14,027,000	24,890,000	-10,305,000	-81,836,000	-66,483,000	-84,473,000	-19,640,000	-18,267,000	-85,231,000	-86,091,000	-101,650,000	-55,433,000	-73,774,000	28,739,000	-16,186,000	31,078,000	32,298,000	23,717,000	33,703,000	-59,132,000	-112,350,000	-62,007,000	-59,806,000	-80,762,000	-76,071,000	-27,655,000	-6,201,000	-43,114,000	-213,905,000	-46,442,000	-17,528,000	-30,995,000	-13,660,000	-14,977,000	15,533,000	-11,978,000	1,603,000	128,247,000	-43,241,000	-118,037,000	-53,462,000	-50,014,000	-26,077,000	-45,091,000	-17,430,000	-60,801,000	-4,353,000	-34,762,000	-1,040,000	-9,646,000	-10,245,000	-8,611,000	18,403,000	-8,236,000	-5,746,000	-5,704,000
yoy	-18.88%	-322.83%	-13.09%	1340.48%	-17.38%	-121.10%	-129.47%	-47.53%	348.00%	-22.00%	-1.88%	-80.68%	-67.05%	15.53%	-399.56%	528.01%	-278.37%	-328.42%	21.17%	-148.03%	-152.56%	-128.75%	-138.25%	-156.35%	-26.78%	47.69%	124.22%	864.46%	87.32%	-64.44%	-40.45%	-64.62%	39.10%	1465.92%	210.09%	-212.84%	158.77%	-952.15%	-111.68%	-135.92%	-89.85%	-103.00%	-356.42%	65.82%	161.78%	206.72%	-17.74%	499.06%	29.71%	1575.96%	530.32%	-57.51%	303.69%	-105.65%	17.12%	78.30%	50.96%
qoq	75.47%	-244.50%	-114.57%	119.55%	-582.02%	-43.64%	-341.53%	-87.41%	23.09%	-21.30%	330.11%	7.52%	-78.57%	-1.00%	-15.31%	83.37%	-24.86%	-356.70%	-277.55%	-152.08%	-3.78%	36.18%	-29.63%	-157.00%	-47.37%	81.19%	3.68%	-25.95%	6.17%	175.07%	345.98%	-85.62%	-79.84%	360.59%	164.96%	-43.45%	126.90%	-8.79%	-196.42%	-229.68%	-847.22%	-98.75%	-396.59%	-63.37%	120.79%	6.89%	91.79%	-42.17%	158.70%	-71.33%	1296.76%	-87.48%	3242.50%	-89.22%	-5.85%	18.98%	-146.79%	-323.45%	43.33%	0.74%
net income margin %	-44.16%	-21.06%	14.26%	-94.66%	-45.09%	7.64%	14.33%	-5.66%	-47.12%	-36.55%	-47.30%	-7.40%	-7.69%	-45.99%	-47.90%	-32.80%	-16.84%	-18.38%	7.45%	-3.66%	5.70%	6.53%	5.54%	11.19%	-27.96%	-50.08%	-27.10%	-26.42%	-36.31%	-34.29%	-11.07%	-2.35%	-16.91%	-110.43%	-17.63%	-5.58%	-10.47%	-4.96%	-5.03%	4.35%	-4.12%	0.58%	89.66%	-101.91%	-392.36%	-209.38%	-252.94%	-110.75%	-202.44%	-84.24%	-294.56%	-18.27%	-110.79%	-6.40%	-81.78%	-Infinity%	-Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%
loss per share:
loss per share, basic and diluted	-0.07			-0.19	-0.1																																																							-0.02	-0.02
weighted-average common shares outstanding, basic and diluted	758,876,415			788,006,992	671,577,429			697,211,592	706,882,189		751,525,007	751,727,383	751,506,257		750,396,263	712,548,661	660,302,426		651,843,074	646,996,891	640,853,200		640,699,982	640,578,794	640,578,794		586,351,045	586,351,045	586,344,207		559,786,382		559,473,838		559,405,309		558,434,153				545,823,434
gain on sale of assets			-101,576,000				-121,493,000							-3,194,000		-15,365,000			-31,508,000
income before income taxes and investment losses		-48,615,750	41,431,000			-11,336,500	48,420,000							-102,182,000	-126,375,000	-86,312,000	-76,650,000	-65,813,000	31,472,000	-11,365,000	31,681,000	45,941,000	20,649,000	39,920,000				-58,451,000				3,029,000				-22,860,000		-7,725,500	-34,151,000	33,389,000		-28,545,500	38,771,000
net income before investment losses		-48,602,750	21,634,000			-16,811,000	24,893,000							-85,207,000	-86,048,000	-101,382,000	-55,384,000	-73,309,000	28,792,000	-16,119,000	31,121,000	32,345,000	23,827,000	33,892,000				-59,535,000				1,012,000				-11,900,000
income per share:
income per share, basic		-0.065	0.03			-0.025	0.04
income per share, diluted		-0.065	0.03			-0.025	0.03
weighted-average common shares outstanding, basic			777,154,808				694,622,466																									559,541,253				559,347,540			552,229,266	547,558,800			500,562,254
weighted-average common shares outstanding, diluted			779,919,259				998,363,636																									559,541,253				564,163,808			552,229,266	557,040,435			514,320,570
other income and (expense), net:
contingent consideration										-13,000	-1,125,000	-34,000	136,000	-627,000	-754,000	175,000	-106,000	-147,000	-497,000	-103,000	-957,000	-5,323,000	1,083,000	1,111,000	-860,000	-14,776,000	-1,109,000	-3,775,000	4,806,000	-4,410,000	1,193,000	-15,358,000	1,759,000	1,052,000	-11,213,000	4,366,000	2,371,000	1,350,000	3,093,000	10,758,000	1,753,000	-1,421,000	1,636,000	-339,000	5,175,000	368,000	19,592,000	1,876,000	2,610,000	2,774,000	252,000	2,577,000	1,344,000	-1,880,000	556,000	965,000	1,144,000
income tax provision						-5,474,500	-23,527,000													-4,754,000	-560,000			-6,028,000	-1,171,000			-1,084,000																		-252,250	-294,000	-101,000		564,500	1,290,000	925,000	43,000	22,250	-128,000	2,000	215,000	49,750	-27,000	-6,000	233,000
loss per share, basic and diluted:
loss per share								-0.01	-0.12	-0.09	-0.11	-0.03	-0.02												-0.09	-0.18	-0.11	-0.1	-0.14	-0.035	-0.05			-0.043	-0.08																							-0.02	-0.03
income per share, basic and diluted:
income per share														-0.12	-0.11	-0.14	-0.08	-0.12	0.04	-0.03	0.05		0.04	0.05
other income and (expense)																	-4,226,000	-2,729,000	-6,354,000	-16,936,000	-6,756,000	-3,415,000	-1,290,000	12,741,000	-17,065,000	4,019,000	-20,933,000	-11,191,000	-2,807,000	-11,392,000	-3,880,000	8,137,000	1,061,000	3,581,000	-8,544,000	3,583,000	5,899,000	7,756,000	-10,528,000	5,123,000	-2,621,000	-15,882,000	46,994,000	-16,777,000	-53,853,000	-20,892,000	-1,459,000	9,279,000	-12,144,000	21,445,000	-38,901,000	16,926,000	-24,056,000	-371,000	-120,000	-427,000	974,000
asset impairment charges																										91,744,000			655,000
loss per share, basic																																-0.01
loss per share, diluted																																-0.01
net income per share																																	-0.08				-0.06				-0.02			-0.09	-0.26	-0.13	-0.11	-0.06	-0.11	-0.03	-0.17			-0.01	-0.03	-0.04	-0.03
earnings per share:
earnings per share, basic																																				-0.03		-0.005	-0.03	0.03		-0.018	0.26
earnings per share, diluted																																				-0.04		-0.005	-0.03	0.02		-0.018	0.25
grant repayment																																													25,889,000
income before investment losses																																						-1,569,000	-14,163,000	17,521,000		-6,741,000	131,749,000
less: net loss attributable to noncontrolling interests																																												-475,000	-925,000	-491,000	-1,345,000	-597,000	-540,000	-630,000	-803,000	-959,000	-547,000
net income attributable to common shareholders																																						-2,855,750	-14,977,000	15,533,000		-7,907,750	128,247,000
loss before investment losses																																									-9,633,000			-42,437,000	-116,276,000	-52,361,000	-49,954,000	-25,707,000	-43,035,000			-1,982,000	-30,872,000							-5,295,000	-5,281,000
net loss attributable to common shareholders																																									-11,978,000			-42,766,000	-117,112,000	-52,971,000	-48,669,000	-25,480,000	-44,551,000	-16,800,000	-59,998,000	-3,394,000	-34,635,000	-1,108,000	-10,206,000	-10,805,000	-9,171,000	17,884,000	-8,836,000	-6,361,000	-6,349,000
other revenue, principally transfer of intellectual property																																										12,138,000	18,350,000
in-process research and development
products																																												22,848,000	15,486,000	18,473,000	17,291,000	21,392,000	19,828,000	17,453,000	16,563,000	18,618,000	15,527,000
revenue from transfer of intellectual property																																												17,673,000	12,529,000	5,000,000			476,000	631,000	1,308,000	2,015,000	12,757,000
costs of revenues																																												14,434,000	10,320,000	11,934,000	11,120,000	12,565,000	12,391,000	12,048,000	11,952,000	13,103,000
weighted-average number of common shares outstanding, basic and diluted		751,132,891				694,019,535				751,765,915				719,060,942				648,077,716				640,655,290				595,454,394								559,160,565				550,846,553				488,065,908		462,253,161	446,480,884	422,014,039	427,577,102	413,339,679	412,909,809	355,095,701	360,638,527	336,732,215	312,932,561	295,750,077	298,103,882	297,836,707	297,543,066	280,673,122	285,582,259	285,135,830	261,042,274
in process research and development																																														2,513,750		10,055,000
net loss attributable to common shareholders before preferred stock dividend																																														-52,971,000	-48,669,000	-25,480,000	-44,551,000	-16,800,000	-59,998,000	-3,394,000	-34,215,000
preferred stock dividend																																																					-420,000	-560,000	-560,000	-560,000	-560,000	-519,000	-600,000	-615,000	-645,000
operating loss from continuing operations																																																		-35,866,000	-19,010,000			-9,712,000	-9,369,000	-9,341,000	-8,847,000	-8,475,000	-5,804,000
loss from continuing operations before income taxes and investment losses																																																		-14,421,000	-57,911,000			-10,083,000	-9,489,000	-9,768,000	-7,873,000
loss from continuing operations before investment losses																																																		-13,835,000	-59,201,000					-9,770,000	-8,088,000	10,795,000	-6,448,000
loss from continuing operations																																																		-17,430,000	-60,801,000			-966,000	-9,829,000	-10,245,000	-8,611,000	10,381,000	-6,749,000
income from discontinued operations, net of tax																																																						-74,000	183,000
income from discontinued operations
income from operations																																																				-17,983,000	-6,773,000
basic and diluted loss per share																																																				-0.01	-0.11
cost of revenues, excluding amortization of intangible assets																																																					11,757,000
gross margin, excluding amortization of intangible assets																																																					19,619,000	7,411,000	4,308,000	3,657,000	3,790,000	1,636,000	2,790,000	3,931,000	3,025,000
operating expenses:
total operating expenses																																																					26,392,000	17,123,000	13,677,000	12,998,000	12,637,000	10,111,000	8,594,000	9,093,000	8,111,000
product sales																																																						7,512,750	11,495,000	9,917,000	8,639,000	5,528,250	6,760,000	10,130,000	8,635,000
other revenue																																																						183,000	300,000	294,000	138,000	18,000	47,000	12,000	13,000
cost of goods sold, excluding amortization of intangible assets																																																						4,757,000	7,487,000	6,554,000	4,987,000	4,158,000	4,017,000	6,211,000	5,623,000
other operating expenses, principally amortization of intangible assets																																																						1,569,250	2,178,000	2,108,000	1,991,000	789,000	945,000	1,020,000	880,000
loss from continuing operation before investment losses																																																						-6,804,750	-9,361,000
revenue:
total revenue																																																								10,211,000	8,777,000	5,794,000	6,807,000	10,142,000	8,648,000
loss from discontinued operations, net of tax																																																										-710,250	-1,487,000
loss from discontinued operations
revenue
operating expenses
other income and
loss from continuing operations before income taxes and investment loss																																																										-3,867,750	-6,475,000
loss per share from continuing operations																																																										-0.015	-0.02
loss before income taxes and investment
loss																																																												-5,301,000

Balance Sheets:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31

assets
current assets:
cash, cash equivalents and current restricted cash	341,881,000	369,074,000	415,198,000	271,718,000	435,999,000	431,936,000	406,400,000
accounts receivable	79,636,000	90,255,000	94,580,000	99,376,000	96,150,000	118,017,000	106,579,000	105,313,000	111,367,000	123,379,000	117,449,000	210,982,000	121,486,000	127,312,000	123,188,000	158,425,000	212,755,000	259,637,000	255,192,000	265,856,000	320,462,000	286,314,000	241,544,000	214,352,000	132,476,000	134,617,000	140,765,000	148,287,000	144,383,000	143,907,000	157,374,000	152,777,000	158,642,000	165,516,000	233,916,000	251,747,000	238,893,000	220,284,000	223,827,000	213,372,000	204,479,000	193,875,000	189,725,000	26,980,000	19,064,000	19,969,000	21,210,000	23,113,000	19,664,000	19,767,000	21,372,000	22,227,000	21,170,000	21,162,000	19,142,000	15,901,000	16,249,000	12,544,000	12,688,000	15,528,000	14,001,000	13,317,000
inventory	64,397,000	65,823,000	64,954,000	66,345,000	64,001,000	56,797,000	59,408,000	60,153,000	59,366,000	65,697,000	68,960,000	73,749,000	75,411,000	74,060,000	71,429,000	83,306,000	99,406,000	86,502,000	112,861,000	134,722,000	159,104,000	132,341,000	111,873,000	72,965,000	58,697,000	53,434,000	50,109,000	48,293,000	44,610,000	42,299,000	43,379,000	46,753,000	49,815,000	49,333,000	46,954,000	48,293,000	47,492,000	47,228,000	43,186,000	42,046,000	40,575,000	39,681,000	40,693,000	20,519,000	18,324,000	16,604,000	16,662,000	18,334,000	18,865,000	18,079,000	19,516,000	19,778,000	23,022,000	22,261,000		17,087,000	18,393,000	13,339,000	10,516,000	16,326,000	18,137,000	19,957,000
other current assets and prepaid expenses	49,448,000	56,729,000	52,398,000	58,883,000	54,441,000	55,339,000	57,249,000	32,288,000	24,652,000	24,519,000	32,209,000	40,950,000	98,691,000	39,962,000	38,516,000	42,563,000	23,274,000	27,170,000	40,858,000	47,627,000	29,980,000	32,313,000	38,398,000	51,125,000	48,754,000	50,542,000	37,301,000	36,533,000	38,994,000	35,052,000	45,346,000	41,651,000	40,946,000	37,113,000	49,324,000	41,946,000	42,495,000	47,356,000	90,408,000	78,506,000
total current assets	535,362,000	581,881,000	627,130,000	583,333,000	737,604,000	662,089,000	629,636,000	357,981,000	391,303,000	309,476,000	357,239,000	433,789,000	406,418,000	394,525,000	413,971,000	494,752,000	754,069,000	823,013,000	557,510,000	547,029,000	599,049,000	523,179,000	428,109,000	360,054,000	274,457,000	324,045,000	292,842,000	344,228,000	435,237,000	317,731,000	289,817,000	321,562,000	349,346,000	343,461,000	430,556,000	472,516,000	459,932,000	483,601,000	502,067,000	505,573,000	453,532,000	454,058,000	517,416,000	278,339,000	394,025,000	142,869,000	163,148,000	183,010,000	205,272,000	242,728,000	241,277,000	230,116,000	237,683,000	78,657,000	87,985,000	92,346,000	99,411,000	99,582,000	117,629,000	127,628,000	142,785,000	54,072,000
property, plant and equipment	72,585,000	73,926,000	74,994,000	74,937,000	71,195,000	70,134,000	72,271,000	66,766,000	64,165,000	75,429,000	78,170,000	78,876,000	80,853,000	82,879,000	79,949,000	78,601,000	81,899,000	79,727,000	107,500,000	106,652,000	139,069,000	140,554,000	134,102,000	130,540,000	127,304,000	127,111,000	128,519,000	137,106,000	139,965,000	144,674,000	147,386,000	150,156,000	148,718,000	146,557,000	142,437,000	133,355,000	126,256,000	122,831,000	125,486,000	128,274,000	133,948,000	131,798,000	126,822,000
intangible assets	496,351,000	516,276,000	535,378,000	555,988,000	568,518,000	616,613,000	641,396,000	659,111,000	680,034,000	740,283,000	758,414,000	782,195,000	803,616,000	823,520,000	835,136,000	862,409,000	890,498,000	321,683,000	433,855,000	445,515,000	456,309,000	475,002,000	486,418,000	499,125,000	513,511,000	528,962,000	564,310,000	581,306,000	597,316,000	614,452,000	631,434,000	648,541,000	667,637,000	683,835,000	714,552,000	731,134,000	746,654,000	763,976,000	781,890,000	804,445,000	625,405,000	638,152,000	660,287,000	94,247,000	59,432,000	62,649,000	65,553,000	69,059,000	71,921,000	74,533,000	77,333,000	79,775,000	82,354,000	95,784,000	82,586,000	75,835,000	75,094,000	76,730,000	14,252,000	18,545,000	19,355,000	9,964,000
in-process research and development	195,000,000	195,000,000	195,000,000	195,000,000	195,000,000	195,000,000	195,000,000	195,000,000	195,000,000	195,000,000	195,000,000	195,000,000	195,000,000	195,000,000	195,000,000	195,000,000		590,200,000	590,200,000	590,200,000	590,200,000	590,200,000	590,200,000	590,200,000	590,200,000	590,200,000	635,000,000	635,569,000	635,561,000	635,572,000	646,339,000	645,714,000	646,386,000	647,347,000	648,377,000	645,957,000	645,058,000	644,713,000	646,970,000	606,035,000	793,626,000	792,275,000	812,723,000	812,446,000	793,000,000	793,152,000	793,214,000	793,326,000	793,339,000	793,341,000	793,312,000	203,052,000	203,030,000
goodwill	482,268,000	484,289,000	484,032,000	484,185,000	476,672,000	529,252,000	535,868,000	530,106,000	530,615,000	598,260,000	594,457,000	597,375,000	597,380,000	595,851,000	573,499,000	578,845,000	519,052,000	520,601,000	674,574,000	677,360,000	676,162,000	680,602,000	675,795,000	671,599,000	669,582,000	671,940,000	695,798,000	699,842,000	698,522,000	700,193,000	713,629,000	714,234,000	719,891,000	717,099,000	715,573,000	712,075,000	705,990,000	704,603,000	700,526,000	691,060,000	746,961,000	743,348,000	761,234,000	289,607,000	223,219,000	224,292,000	224,769,000	226,001,000	226,062,000	226,373,000	222,340,000	82,086,000	82,709,000	80,450,000	49,738,000	40,988,000	40,319,000	39,815,000	6,234,000	6,853,000	6,672,000	5,856,000
investments	10,529,000	14,168,000	13,367,000	13,045,000	12,750,000	54,584,000	100,609,000	101,489,000	40,990,000	16,082,000	19,377,000	27,783,000	41,231,000	28,080,000	77,804,000	108,685,000	9,472,000	10,729,000	11,753,000	8,945,000	10,410,000	15,731,000	14,325,000	26,260,000	10,669,000	20,746,000	11,695,000	24,767,000	32,297,000	31,228,000	42,737,000	45,497,000	41,289,000	40,642,000	32,196,000	34,495,000	37,285,000	41,139,000	38,783,000	34,249,000	35,212,000	34,716,000	34,695,000	21,434,000	22,380,000	22,453,000	26,849,000	33,428,000	35,697,000	30,653,000	24,690,000	26,690,000	28,546,000	15,636,000	14,998,000	14,826,000	10,136,000	6,717,000	5,862,000	4,240,000	4,691,000	5,114,000
operating lease right-of-use assets	45,800,000	46,930,000	45,681,000	46,627,000	47,819,000	54,003,000	62,812,000	61,622,000	63,331,000	68,088,000	44,690,000	34,938,000	36,832,000	38,725,000	39,790,000	42,412,000	42,768,000	44,228,000	33,502,000	36,349,000	38,631,000	37,735,000	36,485,000	38,469,000	39,793,000	39,380,000	35,826,000	29,640,000	33,277,000
other assets	18,901,000	19,474,000	19,926,000	19,874,000	18,769,000	18,537,000	18,511,000	7,796,000	8,578,000	9,080,000	9,333,000	8,943,000	8,340,000	8,679,000	9,636,000	8,898,000	9,100,000	9,534,000	8,744,000	9,600,000	9,745,000	10,060,000	5,857,000	7,487,000	7,026,000	6,888,000	5,528,000	3,770,000	3,126,000	7,222,000	9,652,000	5,246,000	5,627,000	5,615,000	38,299,000	39,162,000	38,893,000	5,756,000	4,305,000	4,385,000	4,522,000	5,267,000		6,013,000	5,073,000	5,838,000	4,673,000	4,910,000	6,520,000	6,861,000	7,003,000	2,784,000	2,863,000	2,777,000	1,870,000	1,244,000	1,267,000	1,287,000	824,000	60,000	33,000	111,000
total assets	1,856,796,000	1,931,944,000	1,995,508,000	1,972,989,000	2,128,327,000	2,200,212,000	2,256,103,000	1,979,871,000	1,974,016,000	2,011,698,000	2,056,680,000	2,158,899,000	2,169,670,000	2,167,259,000	2,224,785,000	2,369,602,000	2,306,858,000	2,399,715,000	2,417,638,000	2,421,650,000	2,519,575,000	2,473,063,000	2,371,291,000	2,323,734,000	2,232,542,000	2,309,272,000	2,369,518,000	2,456,228,000	2,575,301,000	2,451,072,000	2,480,994,000	2,530,950,000	2,578,894,000	2,584,556,000	2,721,990,000	2,768,694,000	2,760,068,000	2,766,619,000	2,800,027,000	2,774,021,000	2,793,206,000	2,799,614,000	3,015,853,000	1,525,491,000	1,512,249,000	1,267,664,000	1,295,242,000	1,327,082,000	1,355,692,000	1,391,516,000	1,382,982,000	641,080,000	653,935,000	289,830,000	250,022,000	230,471,000	231,570,000	229,489,000	151,001,000	160,419,000	176,307,000	77,846,000
liabilities and equity
current liabilities:
accounts payable	44,176,000	41,103,000	50,827,000	56,683,000	59,370,000	47,071,000	62,721,000	82,242,000	71,157,000	69,677,000	66,801,000	87,877,000	80,503,000	66,993,000	49,748,000	56,107,000	94,240,000	82,040,000	94,393,000	88,512,000	162,690,000	100,883,000	65,685,000	44,671,000	55,866,000	62,537,000	77,296,000	60,376,000	51,085,000	47,395,000	65,613,000	69,061,000	64,229,000	74,307,000	66,536,000	62,153,000	74,558,000	53,360,000	58,544,000	61,062,000	73,436,000	72,535,000	77,969,000	16,039,000	10,472,000	8,744,000	8,841,000	10,041,000	14,696,000	13,414,000	13,631,000	11,646,000	11,287,000	10,200,000	7,238,000	4,402,000	4,877,000	4,891,000	2,556,000	2,890,000	4,574,000	7,170,000
accrued expenses	83,476,000	84,406,000	95,603,000	90,555,000	113,209,000	118,357,000	122,806,000	94,516,000	88,772,000	90,086,000	92,368,000	98,604,000	106,058,000	98,269,000	112,015,000	128,254,000	157,316,000	193,493,000	163,926,000	187,172,000	213,119,000	240,869,000	248,422,000	210,111,000	164,939,000	164,925,000	172,734,000	198,382,000	217,534,000	203,513,000	214,907,000	200,992,000	217,133,000	215,102,000	176,300,000	206,403,000	178,866,000	197,955,000	186,076,000	209,848,000	182,342,000	167,899,000	201,113,000	149,843,000	158,763,000	60,912,000	55,554,000	54,964,000	58,772,000	65,874,000	43,269,000	31,045,000	26,673,000	24,656,000	21,794,000	12,650,000	10,389,000	4,956,000	3,678,000	4,033,000	5,557,000	5,739,000
current maturities of operating leases	11,086,000	10,917,000	10,106,000	9,919,000	9,888,000	12,649,000	12,741,000	11,624,000	11,742,000	12,996,000	11,267,000	11,240,000	11,490,000	11,628,000	11,535,000	12,122,000	11,690,000	11,624,000	9,823,000	10,102,000	10,305,000	9,028,000	9,080,000	10,298,000	11,480,000	12,038,000	12,921,000	13,376,000	15,123,000
current portion of lines of credit and notes payable	9,645,000	10,251,000	12,785,000	14,024,000	12,145,000	14,849,000	13,222,000	22,129,000	22,820,000	27,293,000	30,118,000	28,729,000	24,371,000	33,540,000	23,342,000	18,989,000	17,412,000	14,695,000	14,893,000	17,961,000	17,816,000	24,703,000	12,702,000	14,463,000	12,802,000	9,619,000	7,187,000	11,240,000	112,316,000	5,851,000	6,353,000	6,465,000	6,971,000	11,926,000	16,112,000	14,496,000	11,527,000	11,981,000	9,891,000	10,327,000	11,454,000	11,468,000	78,508,000	14,599,000	13,603,000	13,455,000	12,446,000	14,397,000	11,032,000	12,562,000	14,477,000	16,778,000	20,264,000	17,526,000	17,408,000	14,571,000	14,194,000	8,757,000				14,690,000
total current liabilities	148,383,000	146,677,000	169,321,000	171,181,000	295,854,000	193,096,000	211,660,000	219,553,000	204,338,000	200,052,000	200,554,000	226,450,000	222,422,000	213,480,000	267,272,000	215,472,000	309,170,000	330,008,000	283,035,000	303,980,000	403,930,000	375,483,000	335,889,000	279,543,000	245,087,000	249,119,000	270,138,000	283,374,000	396,058,000	288,321,000	317,830,000	306,861,000	318,077,000	301,335,000	258,948,000	283,052,000	264,951,000	263,296,000	254,511,000	281,237,000	267,232,000	251,902,000	357,590,000	180,481,000	182,838,000	83,111,000	76,841,000	79,402,000	84,500,000	91,850,000	71,377,000	59,469,000	58,224,000	52,382,000	46,441,000	31,710,000	29,705,000	18,778,000	20,241,000	21,527,000	24,683,000	27,599,000
operating lease liabilities	35,636,000	36,815,000	36,273,000	37,291,000	38,344,000	48,849,000	52,057,000	49,624,000	50,931,000	54,140,000	34,649,000	24,912,000	26,462,000	27,963,000	29,005,000	30,876,000	31,596,000	33,097,000	28,256,000	30,605,000	32,394,000	29,760,000	28,225,000	28,759,000	28,669,000	27,665,000	23,318,000	16,673,000	18,621,000
long term portion of convertible notes	87,380,000	85,020,000	82,699,000	80,466,000	77,226,000	173,606,000	178,695,000	175,942,000	323,108,000		213,285,000	212,299,000	211,328,000		141,815,000
senior secured royalty financing	246,643,000
deferred tax liabilities	114,562,000	126,241,000	130,341,000	113,328,000	129,435,000	140,799,000	128,412,000	119,120,000	121,635,000	126,773,000	138,007,000	133,049,000	129,668,000	126,426,000	135,073,000	176,741,000	125,030,000	148,487,000	134,247,000	136,416,000	135,244,000	137,208,000	119,182,000	118,979,000	118,600,000	118,717,000	113,479,000	113,334,000	116,009,000	115,193,000	134,112,000	148,255,000	148,732,000	148,729,000	118,799,000	142,212,000	159,286,000	165,331,000	184,493,000	207,595,000	202,680,000	226,036,000	408,213,000
other long-term liabilities	19,582,000		25,160,000	27,807,000	30,011,000
total long-term liabilities	503,803,000	517,308,000	520,697,000	504,904,000	520,810,000	641,668,000	641,026,000	365,001,000	516,870,000	422,427,000	411,558,000	397,101,000	395,438,000	392,131,000	328,445,000	435,331,000	382,804,000	384,581,000	369,036,000	375,085,000	419,131,000	426,029,000	411,632,000	455,848,000	438,836,000	445,394,000	457,451,000	463,923,000	416,506,000	371,460,000	374,521,000	413,593,000	437,553,000	397,843,000	374,006,000	378,813,000	388,147,000	411,515,000	440,124,000	477,144,000	528,100,000	567,918,000	688,895,000	518,024,000	516,838,000	348,812,000	331,057,000	334,855,000	439,943,000	426,687,000	443,679,000	269,127,000	275,933,000
total liabilities	652,186,000	663,985,000	690,018,000	676,085,000	816,664,000	834,764,000	852,686,000	584,554,000	721,208,000	622,479,000	612,112,000	623,551,000	617,860,000	605,611,000	595,717,000	650,803,000	691,974,000	714,589,000	652,071,000	679,065,000	823,061,000	801,512,000	747,521,000	735,391,000	683,923,000	694,513,000	727,589,000	747,297,000	812,564,000	659,781,000	692,351,000	720,454,000	755,630,000	699,178,000	632,954,000	661,865,000	653,098,000	674,811,000	694,635,000	758,381,000	795,332,000	819,820,000	1,046,485,000	698,505,000	699,676,000	431,923,000	407,898,000	414,257,000	524,443,000	518,537,000	515,056,000	328,596,000	334,157,000	86,550,000	79,371,000	54,583,000	52,204,000	44,221,000	22,395,000	23,127,000	26,566,000	28,666,000
equity:
common stock - 0.01 par value...	7,850,000	7,900,000	7,990,000	8,097,000	7,015,000	7,015,000	7,124,000	7,273,000	7,269,000	7,820,000	7,817,000	7,817,000	7,813,000	7,813,000	7,814,000	7,806,000	6,902,000	6,901,000	6,900,000	6,898,000	6,707,000	6,706,000	6,706,000	6,704,000	6,704,000	6,704,000	6,162,000	6,162,000	6,162,000	5,869,000	5,604,000	5,602,000	5,600,000	5,600,000	5,600,000	5,600,000	5,596,000	5,586,000	5,581,000	5,483,000	5,480,000	5,462,000	5,459,000	4,646,000	4,593,000	4,334,000	4,329,000	4,271,000	4,154,000	4,148,000	4,089,000	3,391,000	3,388,000		2,982,000	2,980,000			2,881,000
treasury stock	-1,791,000	-3,176,000	-2,390,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,791,000	-1,911,000	-1,911,000	-1,911,000	-1,911,000	-1,911,000	-3,645,000	-3,645,000	-3,645,000	-4,051,000	-4,051,000	-4,051,000	-4,051,000	-7,300,000	-7,362,000	-7,457,000	-7,457,000	-7,457,000	-7,457,000	-7,457,000	-8,092,000	-8,092,000	-8,092,000	-7,893,000	-7,893,000	-61,000	-61,000
additional paid-in capital	3,571,575,000	3,574,942,000	3,584,789,000	3,596,392,000	3,484,068,000	3,481,364,000	3,516,735,000	3,540,414,000	3,386,147,000	3,433,006,000	3,430,340,000	3,427,094,000	3,424,589,000	3,421,872,000	3,418,763,000	3,413,556,000	3,191,139,000	3,222,487,000	3,218,583,000	3,214,351,000	3,155,648,000	3,152,694,000	3,150,437,000	3,147,030,000	3,145,444,000	3,142,993,000	3,065,059,000	3,061,631,000	3,058,509,000	3,004,422,000	2,907,017,000	2,901,086,000	2,895,191,000	2,889,256,000	2,883,026,000	2,863,025,000	2,856,645,000	2,845,096,000	2,834,300,000	2,736,816,000	2,728,264,000	2,705,385,000	2,696,420,000	1,687,389,000	1,628,818,000	1,529,096,000	1,523,548,000	1,490,071,000	1,384,694,000	1,379,383,000	1,357,235,000	742,097,000	739,778,000	565,201,000	529,958,000	528,468,000	526,023,000	524,814,000	485,181,000	482,910,000	482,521,000	376,008,000
accumulated other comprehensive loss	-27,486,000	-21,017,000	-25,466,000	-24,730,000	-45,006,000	-56,130,000	-39,614,000	-46,652,000	-45,195,000	-38,030,000	-46,495,000	-36,942,000	-37,611,000	-43,323,000	-58,026,000	-49,171,000	-31,415,000	-30,495,000	-19,923,000	-9,932,000	-13,295,000	-4,225,000	-17,451,000	-25,752,000	-30,187,000		-28,774,000	-20,351,000	-23,229,000		-13,138,000	-13,004,000	-539,000		-5,422,000	-14,070,000	-24,953,000	-27,009,000	-16,284,000	-23,431,000	-17,110,000	-22,537,000
accumulated deficit	-2,345,538,000	-2,290,690,000	-2,259,433,000	-2,281,064,000	-2,132,623,000	-2,065,010,000	-2,079,037,000	-2,103,927,000	-2,093,622,000	-2,011,786,000	-1,945,303,000	-1,860,830,000	-1,841,190,000	-1,822,923,000	-1,737,692,000	-1,651,601,000	-1,549,951,000	-1,511,976,000	-1,438,202,000	-1,466,941,000	-1,450,755,000	-1,481,833,000	-1,514,131,000	-1,537,848,000	-1,571,551,000	-1,511,077,000	-1,398,727,000	-1,336,720,000	-1,276,914,000	-1,197,078,000	-1,109,049,000	-1,081,397,000	-1,075,197,000	-1,007,159,000	-792,377,000	-745,935,000	-728,407,000	-729,954,000	-716,294,000	-701,317,000	-716,849,000	-704,871,000	-706,474,000	-834,721,000	-791,955,000	-674,843,000	-621,872,000	-573,203,000	-547,727,000	-503,177,000	-486,377,000	-426,379,000	-422,985,000	-388,770,000	-388,222,000	-378,576,000	-368,333,000	-359,722,000	-378,125,000	-369,889,000	-364,128,000	-358,379,000
total shareholders’ equity	1,204,610,000	1,267,959,000	1,305,490,000	1,296,904,000	1,311,663,000	1,365,448,000	1,403,417,000	1,395,317,000	1,252,808,000	1,389,219,000	1,444,568,000	1,535,348,000	1,551,810,000	1,561,648,000	1,629,068,000	1,718,799,000	1,614,884,000	1,685,126,000	1,765,567,000	1,742,585,000	1,696,514,000	1,671,551,000	1,623,770,000	1,588,343,000	1,548,619,000	1,614,759,000	1,641,929,000	1,708,931,000	1,762,737,000	1,791,291,000	1,788,643,000	1,810,496,000	1,823,264,000	1,885,378,000	2,089,036,000	2,106,829,000	2,106,970,000	2,091,808,000	2,105,392,000	2,015,640,000	1,997,874,000	1,979,794,000	1,969,368,000	826,986,000	812,573,000	835,741,000	887,344,000	912,825,000	831,249,000	876,410,000	870,727,000	314,482,000	320,817,000	179,386,000	146,265,000	151,502,000	154,980,000	160,882,000	102,478,000	111,164,000	123,613,000	23,052,000
total liabilities and equity	1,856,796,000	1,931,944,000	1,995,508,000	1,972,989,000	2,128,327,000	2,200,212,000	2,256,103,000	1,979,871,000	1,974,016,000	2,011,698,000	2,056,680,000	2,158,899,000	2,169,670,000	2,167,259,000	2,224,785,000	2,369,602,000	2,306,858,000	2,399,715,000	2,417,638,000	2,421,650,000	2,519,575,000	2,473,063,000	2,371,291,000	2,323,734,000	2,232,542,000	2,309,272,000	2,369,518,000	2,456,228,000	2,575,301,000	2,451,072,000	2,480,994,000	2,530,950,000	2,578,894,000	2,584,556,000	2,721,990,000	2,768,694,000	2,760,068,000	2,766,619,000	2,800,027,000	2,774,021,000	2,793,206,000	2,799,614,000	3,015,853,000	1,525,491,000	1,512,249,000	1,267,664,000	1,295,242,000	1,327,082,000	1,355,692,000
current portion of convertible notes					101,242,000	170,000	170,000	170,000	170,000					3,050,000	70,632,000
senior secured notes		246,433,000	246,224,000	246,012,000	245,794,000	245,576,000	245,358,000
other long-term liabilities, principally contingent consideration and lines of credit		22,799,000				32,838,000
assets held for sale				87,011,000	87,013,000			119,651,000	120,279,000								316,353,000	314,994,000		33,067,000
other long-term liabilities, principally contract liabilities, contingent consideration and lines of credit							36,504,000	20,315,000	21,196,000	27,189,000	25,617,000	26,841,000	27,980,000	27,371,000	22,552,000	16,237,000	15,658,000	15,062,000	20,990,000	24,866,000	26,711,000	37,072,000				87,804,000				198,968,000
cash and cash equivalents								40,576,000	75,639,000	95,881,000	138,621,000	108,108,000	110,830,000	153,191,000	180,838,000	210,458,000	102,281,000	134,710,000	148,599,000	65,757,000	89,503,000	72,211,000	36,294,000	21,612,000	34,530,000	85,452,000	64,667,000	111,115,000	207,250,000	96,473,000	43,718,000	80,381,000	99,943,000	91,499,000	100,362,000	130,530,000	131,052,000	168,733,000	144,646,000	156,015,000	174,973,000	193,598,000	212,144,000	221,217,000	348,192,000	96,907,000	118,258,000	134,010,000	156,396,000	185,798,000	155,834,000	119,061,000	181,596,000	27,361,000	23,428,000	38,171,000	47,118,000	71,516,000	47,235,000	38,849,000	47,879,000	18,016,000
liabilities associated with assets held for sale								8,872,000	9,677,000									28,156,000
convertible notes										214,325,000				210,371,000		211,477,000	210,520,000	187,935,000	185,543,000	183,198,000	224,782,000	221,989,000	219,194,000	216,457,000	213,805,000	211,208,000	208,695,000	206,165,000	203,711,000
liabilities associated with assets held-for-sale																	28,512,000			233,000
other long-term liabilities, principally contract liabilities, contingent consideration and line of credit																							45,031,000	91,653,000	77,762,000		111,959,000	127,751,000	78,165,000		183,812,000	209,444,000	233,622,000
accumulated other comprehensive income																										-22,070,000				-20,131,000				-528,000									-20,992,000	-18,880,000	-17,503,000	-12,392,000	-8,697,000	304,000	1,399,000	3,418,000	3,237,000	2,830,000	8,093,000	7,356,000	9,004,000	6,722,000	2,406,000	907,000	434,000	3,157,000	2,424,000	2,921,000
current portion of 2033 senior notes																														31,562,000	30,957,000	30,343,000	29,744,000
2023 convertible notes and 2033 senior notes																														57,299,000	56,597,000	55,894,000	55,199,000
2033 senior notes, net of discount																																		29,160,000	28,590,000
other long-term liabilities, principally deferred revenue, contingent consideration and lines of credit																																		219,954,000
other long-term liabilities, principally deferred revenue, contingent consideration and line of credit																																			226,617,000	201,843,000
2033 senior notes and estimated fair value of embedded derivatives, net of discount																																				34,758,000	39,285,000	43,701,000	51,537,000	45,233,000	49,608,000
other long-term liabilities, principally deferred revenue and line of credit																																					189,576,000	202,483,000	204,094,000	224,316,000	275,812,000
marketable securities																																								15,634,000											25,004,000	50,027,000			18,923,000	17,117,000	14,997,000		40,182,000	54,998,000	59,983,000
prepaid expenses and other current assets																																									33,505,000	26,904,000	74,854,000	9,623,000	8,445,000	9,389,000	7,018,000	7,553,000	10,347,000	19,084,000	19,551,000	19,023,000	11,895,000	7,873,000	5,004,000	4,070,000	2,654,000	2,179,000	1,729,000	1,927,000	2,785,000	2,782,000
2033 senior notes, net of discount and estimated fair value of embedded derivatives																																										49,412,000	44,206,000	109,203,000	106,673,000	131,454,000	114,883,000	116,365,000	224,801,000
other long-term liabilities, principally deferred revenue																																										292,470,000
total shareholders’ equity attributable to opko																																										1,979,794,000	1,970,768,000	834,789,000	819,902,000	842,144,000	893,257,000	917,392,000
noncontrolling interests																																											-1,400,000	-7,803,000	-7,329,000	-6,403,000	-5,913,000	-4,567,000	-3,971,000	-3,431,000	-2,801,000	-1,998,000	-1,039,000	-492,000
other assets, principally deferred tax assets																																											102,676,000
other long-term liabilities, principally deferred revenue and contingent consideration																																											236,476,000
property, plant, equipment, and investment properties																																												23,405,000	15,120,000	16,411,000	17,036,000	17,348,000	16,881,000	17,027,000	17,027,000	16,577,000		16,526,000
other long-term liabilities, principally deferred revenue and deferred tax liabilities																																												408,821,000	410,165,000
other long-term liabilities, principally contingent consideration and deferred tax liabilities																																														217,358,000	216,174,000	218,490,000	215,142,000	214,775,000	234,762,000	80,603,000	79,512,000	34,168,000	32,930,000	22,873,000	22,499,000	25,443,000
total shareholders’ equity attributable to parent																																																	835,220,000
liabilities, series d preferred stock, and equity
3.00% convertible senior notes, net of discount and estimated fair value of embedded derivatives																																																		211,912,000	208,917,000	188,524,000	196,421,000
commitments and contingencies:
series d preferred stock - 0.01 par value...																																																							24,386,000	24,386,000			26,128,000
series a preferred stock - 0.01 par value...
series c preferred stock - 0.01 par value...
total equity																																																		872,979,000	867,926,000	312,484,000	319,778,000	178,894,000
total liabilities, series d preferred stock, and equity																																																		1,391,516,000	1,382,982,000	641,080,000	653,935,000
current assets
property, equipment, and investment properties																																																					16,750,000
current liabilities
commitments and contingencies
equity
current assets of discontinued operations																																																										4,000	5,279,000
liabilities, series d preferred stock and equity
current liabilities of discontinued operations																																																								87,000	245,000	174,000	1,460,000
series d preferred stock – 0.01 par value...																																																						24,386,000			24,386,000	24,386,000
series a preferred stock – 0.01 par value...
series c preferred stock – 0.01 par value...
common stock – 0.01 par value...																																																						3,056,000			2,976,000	2,975,000
total liabilities, series d preferred stock and equity																																																						289,830,000
inventories																																																							21,488,000
property and equipment																																																							12,845,000	5,232,000	5,343,000	5,358,000	3,271,000	3,093,000	2,771,000	2,729,000
liabilities, series d preferred stock, and shareholders’ equity
current liabilities of discounted operations																																																							1,000
shareholders’ equity:
total liabilities, series d preferred stock, and shareholders’ equity																																																							250,022,000	230,471,000	231,570,000	229,489,000	151,001,000	160,419,000	176,307,000
shareholders’ equity
assets of discontinued operations																																																											2,929,000
current portion of lines of credit																																																											12,547,000	14,604,000	14,552,000
long-term liabilities																																																											2,154,000	1,600,000	1,883,000
series d preferred stock — 0.01 par value...																																																												26,128,000	26,128,000	26,128,000
series a preferred stock — 0.01 par value...																																																													7,000	9,000
series c preferred stock — 0.01 par value...
common stock — 0.01 par value...																																																												2,879,000	2,850,000	2,554,000
liabilities, series d preferred stock and shareholders’ equity
long-term liabilities — interest payable to related party
other long-term liabilities, principally deferred tax liabilities																																																														1,067,000
line of credit with related party, net of unamortized discount of 0 and 68, respectively
total liabilities, series d preferred stock and shareholders’ equity																																																														77,846,000

Cashflow Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31

cash flows from operating activities:
net loss	-54,848,000	-31,257,000	21,631,000	-148,441,000	-67,613,000	14,027,000	24,890,000	-10,305,000	-81,836,000	-66,483,000	-84,473,000	-19,640,000	-18,267,000										23,717,000	33,703,000	-59,132,000	-112,350,000	-62,007,000	-59,806,000	-80,762,000	-76,071,000	-27,654,000	-6,201,000	-43,114,000	-213,905,000			-30,995,000	-13,660,000			-11,978,000	1,603,000	128,247,000	-43,241,000	-118,037,000	-53,462,000	-50,013,000	-26,072,000	-45,091,000	-17,430,000	-60,801,000	-4,353,000	-34,762,000	-1,040,000	-9,646,000	-10,243,000	-8,611,000
adjustments to reconcile net loss to net cash from operating activities:
depreciation and amortization	22,201,000	22,373,000	22,740,000	23,027,000	23,487,000	24,039,000	24,163,000	24,154,000	25,820,000	25,982,000	26,322,000	26,547,000	26,446,000	26,460,000	26,386,000	27,995,000	27,814,000	19,191,000	18,964,000	20,572,000	19,989,000	20,067,000	20,977,000	22,266,000	22,052,000	22,526,000	23,804,000	23,661,000	23,816,000	23,904,000	23,922,000	24,761,000	24,757,000	25,416,000	25,396,000	25,551,000	25,730,000	23,964,000	25,832,000	24,581,000	22,199,000	22,175,000	12,388,000	4,160,000	3,525,000	3,658,000	3,678,000	4,027,000	3,564,000	4,568,000	3,768,000	3,451,000	3,429,000	2,713,000	2,665,000	2,454,000	2,328,000	972,000	776,000	1,085,000	997,000
non-cash interest	2,433,000	2,391,000	2,309,000	56,908,000	4,649,000	4,794,000	4,615,000	4,295,000	3,843,000	693,000	693,000	686,000	678,000	693,000	693,000	686,000	678,000	2,225,000	2,183,000	2,396,000	2,585,000	2,355,000	2,617,000	2,539,000	2,483,000	4,173,000	1,690,000	-142,000	3,010,000	1,344,000	1,361,000	1,355,000	843,000	631,000	650,000	654,000	640,000	636,000	655,000	659,000	749,000
amortization of deferred financing costs	137,000	137,000	138,000	4,529,000	430,000	646,000	382,000	427,000	519,000	314,000	310,000	302,000	296,000	298,000	294,000	288,000	281,000	182,000	179,000	202,000	222,000	221,000	215,000	208,000	203,000	489,000	198,000	-97,000	405,000	32,000	56,000	56,000	43,000	56,000	56,000	56,000	56,000	62,000	101,000	37,000	37,000	37,000	280,000	144,000	751,000	100,000	100,000	1,630,000	177,000	177,000	650,000	198,000	145,000
losses from investments in investees	2,000	17,000	3,000	0	9,000	11,000	4,000	0	3,000	8,000	20,000	42,000	37,000	24,000	43,000	267,000	49,000	466,000	53,000	67,000	43,000	47,000	110,000	189,000	134,000	481,000	294,000	271,000	1,854,000	2,955,000	1,873,000	7,213,000	2,456,000	2,700,000	4,013,000	5,627,000	2,131,000	2,505,000	814,000	1,988,000	2,345,000	1,038,000	3,502,000	804,000	1,761,000	1,101,000	60,000	370,000	2,056,000	3,595,000	1,600,000	2,371,000	3,890,000
equity-based compensation – employees and non-employees	2,735,000	2,917,000	2,969,000	2,212,000	2,616,000	3,065,000	2,784,000	2,609,000	2,590,000	2,667,000	3,219,000	2,810,000	2,717,000	3,194,000	3,390,000	4,308,000	7,617,000	3,703,000	3,822,000	3,460,000	2,647,000	2,170,000	2,740,000	1,586,000	2,451,000	2,414,000	3,428,000	3,122,000	4,457,000	5,170,000	5,077,000	5,578,000	5,936,000	6,015,000	6,448,000	6,151,000	9,693,000	7,754,000	8,834,000	8,798,000	17,307,000	8,309,000	3,675,000	6,708,000	7,382,000	4,691,000	3,095,000	3,414,000	3,579,000	3,572,000	408,000	1,798,000	5,205,000				1,180,000
realized gain on disposal of fixed assets and sales of equity securities	-34,000		12,000	-72,000	-3,786,000
change in fair value of equity securities and derivative instruments	3,934,000	-824,000	-287,000	-646,000	2,380,000	-19,803,000	-35,378,000	-60,499,000	1,251,000	3,241,000	8,260,000	13,276,000	-7,130,000	49,709,000	30,402,000	72,425,000	1,299,000	2,048,000	1,046,000	1,152,000	-279,000		7,768,000	-15,774,000	9,259,000		11,747,000	7,256,000	-1,825,000	7,822,000	473,000	-11,718,000	-3,101,000
deferred income tax provision	-7,890,000	-10,149,000				7,049,000	12,172,000	-1,797,000	-2,680,000									7,781,000	-101,000	3,512,000	-1,033,000	13,666,000	946,000	415,000	613,000	2,259,000	1,897,000														-22,244,000
changes in assets and liabilities:
accounts receivable	9,526,000	6,709,000	4,389,000	-3,815,000	22,930,000	-15,900,000	327,000	5,835,000	9,518,000	-5,330,000	90,563,000	-89,186,000	7,364,000	-1,450,000	34,188,000	51,443,000	44,421,000	-22,702,000	7,582,000	55,590,000	-35,238,000	-43,182,000	-25,716,000	-80,776,000	-763,000	4,119,000	7,655,000	-3,959,000	-439,000	12,696,000	-4,739,000	5,683,000	6,757,000	71,605,000	17,271,000	-13,094,000	-17,771,000	3,337,000	-10,586,000	-8,464,000	-9,924,000	-15,381,000	-9,200,000	-4,709,000	-103,000	221,000	181,000	-3,764,000	-557,000	1,478,000	928,000	-1,094,000	-558,000	947,000	2,497,000	10,000	-2,691,000	804,000	-449,000	-1,476,000	-598,000
inventory	191,000	1,173,000	624,000	-478,000	-5,437,000	-2,235,000	4,720,000	-542,000	2,274,000	11,115,000	1,333,000	1,443,000	1,306,000	2,348,000	8,450,000	12,327,000	-9,463,000	16,430,000	18,071,000	24,095,000	-27,912,000	-17,077,000	-38,660,000	-13,074,000	-8,831,000	-2,590,000	-3,318,000	-3,750,000	-2,475,000	533,000	3,163,000	690,000	204,000	-5,268,000	2,172,000	-393,000	-50,000	-3,881,000	-963,000	-1,611,000	-152,000	528,000	-3,150,000	-647,000	-2,610,000	-653,000	314,000	263,000	-1,676,000	940,000	-261,000	2,652,000	-1,439,000	-1,364,000	-1,122,000	1,112,000	-4,433,000	-1,910,000	863,000	1,826,000	1,391,000
other current assets and prepaid expenses	6,969,000	-4,137,000	1,035,000	-5,053,000	2,735,000	4,416,000	-578,000	-7,265,000	-552,000	-3,056,000	8,941,000	60,181,000	-58,902,000	561,000	2,525,000	-9,114,000	2,612,000	15,216,000	166,000	-15,319,000	1,415,000	7,393,000	15,730,000	-1,890,000	-729,000	-8,930,000	-5,032,000	2,522,000	-46,000	6,580,000	-574,000	-9,175,000	5,445,000	13,028,000	-6,549,000	-1,000,000	4,692,000	41,572,000	-10,001,000
other assets	-126,000	121,000	412,000	457,000	-967,000	-327,000	680,000	-123,000	7,000	2,378,000	-751,000	-2,687,000	772,000	1,724,000	471,000	-771,000	511,000	-755,000	-373,000	133,000	1,255,000	-177,000	-209,000	-121,000	60,000	169,000	104,000	379,000	-243,000	4,564,000	-4,487,000	-15,000	-131,000	-1,923,000	-195,000	-19,000	-235,000	-1,497,000	-1,134,000	-715,000	1,447,000	-1,567,000	1,774,000	-3,000	-509,000	-7,843,000	554,000	2,482,000	1,429,000	-1,069,000	428,000	26,000	71,000	-438,000	66,000	4,000	7,000	-37,000	35,000	-62,000	80,000
accounts payable	3,496,000	-17,060,000	-5,244,000	-3,388,000	11,475,000	-14,135,000	-20,215,000	10,899,000	2,789,000	2,637,000	-20,019,000	7,451,000	12,759,000	15,612,000	-5,492,000	-35,651,000	16,143,000	-6,101,000	6,905,000	-73,882,000	62,231,000	33,898,000	20,014,000	-11,888,000	-4,865,000	-14,961,000	17,710,000	9,174,000	3,713,000	-16,754,000	-1,237,000	2,114,000	-10,206,000	8,158,000	2,574,000	-10,100,000	19,539,000	-3,678,000	-2,936,000	-12,856,000	-349,000	17,382,000	-42,605,000	4,994,000	2,107,000	-2,000	-542,000	-4,787,000	1,479,000	-474,000	1,970,000	436,000	-103,000	1,578,000	465,000	-525,000	-271,000	1,868,000	596,000	-1,761,000	-2,487,000
foreign currency measurement	126,000	4,843,000	-2,676,000	-1,348,000	-641,000	7,474,000	-6,213,000	1,413,000	1,225,000	-1,060,000	1,342,000	1,037,000	-2,355,000	-8,172,000	6,246,000	2,098,000	2,197,000	-37,000	4,914,000	-3,478,000	946,000	-2,403,000	1,295,000	-2,133,000	56,000	-218,000	16,000	154,000	-23,000	237,000	134,000	-66,000	-11,000	-863,000	378,000	299,000	-69,000	57,000	-28,000	-152,000	-253,000	203,000	476,000	-173,000	473,000	-63,000	1,832,000	152,000	-976,000	-977,000	-1,859,000	790,000	-340,000	290,000	-95,000	349,000	-458,000
accrued expenses and other liabilities	-8,162,000	-3,776,000	-420,000	-24,246,000	-19,397,000	3,731,000	41,513,000	4,486,000	-1,047,000	-3,974,000	-6,445,000	-4,474,000	9,547,000	-8,150,000	-12,653,000	-33,801,000	-36,177,000	31,964,000	-16,527,000	-22,034,000	-27,126,000	-7,160,000	41,403,000	43,737,000	3,848,000	1,002,000	-2,333,000	-10,155,000	12,250,000	6,274,000	11,261,000	-6,991,000	-8,829,000	42,333,000	-8,055,000	12,187,000	-16,024,000	32,021,000	2,563,000	20,326,000	13,126,000	-27,286,000	34,047,000	-1,672,000	4,413,000
net cash from operating activities	-19,310,000	-25,921,000	-34,647,000	-83,420,000	-34,554,000	-44,409,000	-77,079,000	-26,435,000	-35,566,000	-38,294,000	33,109,000	-365,000	-22,647,000	-31,620,000	-32,236,000	-11,477,000	-19,856,000	-5,643,000	33,396,000	-15,453,000	26,037,000	34,258,000	63,011,000	-14,423,000	-43,370,000	-46,037,000	-23,866,000	-53,631,000	-48,988,000	-34,659,000	-21,883,000	-17,079,000	-35,520,000	2,110,000	-37,607,000	-22,664,000	-33,919,000	30,306,000	-31,896,000	42,842,000	-9,206,000	-9,351,000	-31,363,000	-34,055,000	238,793,000	-24,761,000	-21,077,000	-15,495,000	-29,046,000	-26,050,000	-11,472,000	-5,925,000	-14,745,000	-5,728,000	-1,927,000	-6,261,000	-11,499,000	-6,588,000	-3,346,000	-3,881,000	-4,685,000
cash flows from investing activities:
investments in investees		0	0	335,000	-8,000,000					0	0	0	-5,000,000													0	0	0	-1,200,000	0	0	0	-1,000,000	-5,000,000	-1,625,000			-5,253,000	-3,250,000	-5,671,000	-250,000	-1,375,000	-655,000			0	-89,000	0	-500,000	-4,100,000	0	-10,841,000	-2,500,000	-696,000	0	0	-2,700,000
proceeds from sale of equity securities			0	0	51,655,000																									0	230,000	0	1,286,000													0	0	34,000	1,297,000	18,928,000
proceeds from the sale of property, plant and equipment	33,000	93,000	13,000	114,000	67,000	73,000	66,000	55,000	48,000	1,604,000	267,000	522,000	320,000	450,000	631,000	522,000	348,000	51,000	65,810,000	105,000	60,000	53,000	127,000	58,000	7,000	119,000	243,000			153,000	230,000	299,000	541,000	3,292,000	581,000	303,000	3,095,000	319,000	374,000											5,000
capital expenditures	-1,833,000	-2,666,000	-3,135,000	-3,283,000	-3,194,000	-5,413,000	-7,937,000	-7,217,000	-4,443,000	-3,022,000	-4,203,000	-6,013,000	-3,037,000	-6,336,000	-7,612,000	-5,379,000	-5,251,000	-6,730,000	-7,234,000	-8,947,000	-9,245,000	-6,797,000	-9,736,000	-11,523,000	-5,626,000	-3,875,000	-2,434,000	-3,500,000	-2,932,000	-3,035,000	-12,031,000	-6,819,000	-5,973,000	-14,463,000	-15,256,000	-7,268,000	-9,537,000	-1,532,000	-4,149,000	-3,054,000	-9,812,000	-6,424,000	-2,983,000	-1,076,000	-363,000	-799,000	-1,468,000	-1,606,000	-861,000	-971,000	-937,000	-1,299,000	-755,000	-408,000	-656,000	-233,000	-175,000	-704,000	-707,000	-434,000	-108,000
free cash flows	-21,143,000	-28,587,000	-37,782,000	-86,703,000	-37,748,000	-49,822,000	-85,016,000	-33,652,000	-40,009,000	-41,316,000	28,906,000	-6,378,000	-25,684,000	-37,956,000	-39,848,000	-16,856,000	-25,107,000	-12,373,000	26,162,000	-24,400,000	16,792,000	27,461,000	53,275,000	-25,946,000	-48,996,000	-49,912,000	-26,300,000	-57,131,000	-51,920,000	-37,694,000	-33,914,000	-23,898,000	-41,493,000	-12,353,000	-52,863,000	-29,932,000	-43,456,000	28,774,000	-36,045,000	39,788,000	-19,018,000	-15,775,000	-34,346,000	-35,131,000	238,430,000	-25,560,000	-22,545,000	-17,101,000	-29,907,000	-27,021,000	-12,409,000	-7,224,000	-15,500,000	-6,136,000	-2,583,000	-6,494,000	-11,674,000	-7,292,000	-4,053,000	-4,315,000	-4,793,000
net cash from investing activities	-1,800,000	-2,046,000	194,648,000	-2,834,000	40,528,000	115,987,000	247,784,000	-7,162,000	-4,395,000	-1,418,000	-3,572,000	-5,491,000	-7,717,000	-7,872,000	-4,682,000			-8,679,000	54,576,000	-8,842,000	-1,106,000	-6,744,000	5,501,000	-11,465,000	-5,619,000	-3,756,000	-2,191,000	-3,191,000	-4,132,000	-2,882,000	-11,571,000	-6,520,000	-5,146,000	-13,954,000	-16,301,000	-9,970,000	-6,442,000	-6,479,000	19,486,000	-23,647,000	-10,062,000	-7,937,000	7,174,000	-98,095,000	-363,000	-799,000	-1,545,000	-3,067,000	-264,000		45,292,000	-53,199,000	-649,000	8,430,000	-10,801,000	-4,526,000	-17,872,000	39,143,000	12,100,000
cash flows from financing activities:
share repurchase	-4,767,000	-13,507,000	-15,278,000			-16,464,000	-23,759,000	0	-50,000,000
proceeds from the exercise of common stock options			0	-211,000	88,000		0				28,000				-463,000
borrowings on lines of credit	8,486,000	8,528,000	7,869,000	11,026,000	5,610,000	10,973,000	130,648,000	154,108,000	163,703,000	156,360,000	173,468,000	176,562,000	165,288,000	165,971,000	209,081,000	-964,699,000	1,649,166,000	358,072,000	343,844,000	510,584,000	472,213,000	408,787,000	305,428,000	207,253,000	186,398,000	195,427,000	59,658,000	4,235,000	35,460,000	4,449,000	3,651,000	12,206,000	6,611,000	16,877,000	30,020,000	37,699,000	7,825,000	6,591,000	6,320,000	4,248,000	5,248,000	149,980,000	100,321,000	5,880,000	5,158,000	7,117,000	5,068,000	10,008,000	4,250,000	9,964,000	9,259,000	6,926,000	8,428,000
repayments of lines of credit	-8,876,000	-13,227,000	-8,797,000	-9,841,000	-9,546,000	-9,760,000	-141,045,000	-156,015,000	-168,241,000	-160,112,000	-171,391,000	-172,799,000	-175,407,000	-155,741,000	-200,173,000	977,333,000	-1,657,193,000	-357,441,000	-348,325,000	-510,477,000	-479,713,000	-400,766,000	-360,558,000	-194,365,000	-188,009,000	-200,845,000	-79,653,000	-43,511,000	-35,313,000	-6,246,000	-7,511,000	-8,504,000	-12,420,000	-12,867,000	-7,118,000	-6,008,000	-7,517,000	-7,277,000	-9,560,000	-41,992,000	-7,349,000	-150,811,000	-93,522,000	-5,173,000	-4,849,000	-6,546,000	-7,252,000	-8,586,000	-5,985,000	-11,291,000
settlement of convertible notes		0	62,208,000
net cash from financing activities	-5,157,000			-79,489,000	-4,022,000	-40,472,000	206,140,000	-2,115,000	20,613,000	-3,751,000	2,105,000	3,462,000	-13,119,000	10,144,000	8,444,000	12,274,000	-7,891,000	832,000	-4,256,000	265,000	-7,192,000	8,108,000	-54,461,000	12,888,000	-1,611,000	70,644,000	-19,995,000	-39,276,000	163,875,000	90,703,000	-3,005,000	4,020,000	49,191,000	4,226,000	22,902,000	31,741,000	2,174,000	1,778,000	960,000	-37,986,000	53,000	-171,000	14,694,000	4,670,000	13,812,000	4,129,000	7,135,000	-3,905,000	-96,000	17,037,000	2,813,000	-3,317,000	169,641,000	1,048,000	-1,774,000	1,879,000	4,878,000	-8,356,000	-146,000	-9,744,000	105,163,000
effect of exchange rate changes on cash, cash equivalents and restricted cash	-908,000	174,000	-316,000	1,461,000	2,110,000	-5,556,000
net increase in cash, cash equivalents and restricted cash	-27,175,000				4,062,000
cash, cash equivalents and restricted cash at beginning of period	382,742,000	0	0	0	445,615,000	0
cash, cash equivalents and restricted cash at end of period	355,567,000	-46,132,000	143,479,000	-164,282,000	449,677,000	25,550,000
supplemental information:
interest paid	9,603,000	7,730,000	10,139,000	6,305,000	13,762,000	7,901,000	9,465,000	392,000	3,125,000	-2,613,000	6,544,000	374,000	3,830,000	401,000	3,465,000	134,000	3,420,000	129,000	3,503,000	194,000	4,689,000	251,000	5,079,000	566,000	5,012,000	789,000	5,673,000	4,900,000	511,000	445,000	846,000	144,000	641,000	-96,000	661,000	198,000	550,000	371,000	1,619,000	277,000	623,000	1,655,000	1,193,000	156,000	1,568,000	1,054,000	2,451,000	351,000	2,420,000		2,808,000	76,000	242,000		272,000	164,000	177,000		289,000	254,000	65,000
income taxes paid (refunded)	-2,573,000																																																377,000
impairment of intangible assets		0
realized loss on disposal of fixed assets and sales of equity securities						-53,908,000	-9,420,000	-22,000	-47,000	-123,000	-631,000	230,000	1,845,000	359,000	-337,000	-538,000	61,000	1,562,000	-32,338,000	-107,000	-3,039,000		-10,328,000	54,000	102,000
loss on conversion convertible senior notes						-7,353,000	-32,000	0	757,000
inducement expense and loss on debt conversion		0	0
change in fair value of contingent consideration										-13,000	-1,125,000	-34,000	136,000	-627,000	-754,000	175,000	-106,000	-147,000	-497,000	-102,000	-957,000	-5,323,000	1,083,000	1,111,000	-860,000	-14,776,000	-1,109,000	-3,775,000	4,806,000	-4,410,000	1,193,000	-15,358,000	1,759,000	1,052,000	-11,213,000	4,367,000	2,371,000	1,350,000	3,093,000	10,758,000	1,753,000	-1,421,000	1,635,000	-339,000	5,175,000	368,000	19,592,000	1,876,000	2,610,000	2,774,000	252,000	2,577,000	1,344,000	-2,339,000
gain on sale of assets		0				0
changes in assets and liabilities, net of the effects of acquisitions:
proceeds from sale of investments																		0	0	0	8,079,000	0
proceeds from labcorp sale						0
issuance of 3.00% convertible senior notes						0	0	0	230,000,000																																												170,184,000
issuance of 2044 notes						0
debt issuance costs						0	-4,823,000	0	-8,562,000									0								0	0	0	-7,762,000
net activity from the exercise of common stock options and warrants
repurchase of 2029 convertible notes		0				-25,221,000
income taxes paid, net of refunds		3,839,000	763,000	17,802,000	2,059,000	6,207,000	2,225,000	513,000	1,063,000	4,535,000	-1,508,000	208,000	477,000	3,566,000	-176,000	3,584,000	1,063,000	460,000	1,819,000	2,220,000	1,470,000	-1,051,000	356,000	-1,007,000	799,000	-436,000	971,000	1,110,000	1,022,000	-5,293,000	-1,368,000	2,959,000	2,292,000
operating lease right-of-use assets obtained in exchange for lease obligations										23,397,000
assets acquired by finance leases										-510,000	532,000	-779,000	960,000
non-cash financing:
shares issued upon the conversion of:
common stock options and warrants, surrendered in net exercise														86,000	527,000											0	0	0	20,000	0	0			0	0	850,000	696,000	0	25,000	290,000	35,000	128,000	2,000	1,000	14,238,000	0
fair value of shares included in consideration from genedx holdings
purchase of marketable securities																																			-1,000			-13,000	-1,000											0	0			3,117,000	-11,806,000	-2,120,000	-14,997,000	0	-30,180,000	-9,998,000	-59,983,000
proceeds from labcorp sales including escrow released
net cash (provided by) used in financing activities
net decrease in cash, cash equivalents and restricted cash			143,479,000			25,550,000
common stock options, warrants, and restricted stock units surrendered in net exercise			0				0
deferred income tax benefit				-15,713,000	-7,424,000						5,554,000	1,651,000	102,000		-39,941,000	13,414,000	-22,356,000												-352,000		-12,515,000	683,000	-2,709,000		-23,327,000	-13,803,000	-9,236,000		-21,983,000												405,000	-700,000	98,000
redemption of 2025 notes and 2033 senior notes					-174,000	0	0	0	-146,287,000
acquisition of businesses, net of cash acquired
issuance of common stock for acquisition of modex														0	2,288,000
operating lease right-of-use assets in exchange for lease obligations
fair value of shares received related to milestone achieved from genedx holdings
contract liabilities										-129,000	-4,000	0	2,000	-256,000	-56,000	-13,000	-4,000	-2,895,000	-5,591,000	-6,635,000	-790,000	-672,000	-691,000	5,425,000	-9,451,000	-12,442,000	-19,845,000	-18,942,000	-18,073,000	-10,733,000	-19,719,000	-15,454,000	-15,358,000
effect of exchange rate changes on cash and cash equivalents								649,000	-894,000	723,000	-1,129,000	-328,000	1,122,000	1,701,000	-1,146,000	-1,115,000	221,000	-399,000	-874,000	284,000	-447,000	295,000	631,000	82,000	-322,000	-66,000	-396,000	-37,000	22,000	-407,000	-204,000	17,000	-81,000	-1,245,000	838,000	371,000	506,000	-1,518,000	81,000																-241,000	-39,000	95,000		-222,000	45,000	14,000
net decrease in cash and cash equivalents								-35,063,000	-20,242,000				-42,361,000																110,777,000		-36,663,000				-30,168,000	-522,000	-37,681,000
cash and cash equivalents at beginning of period								0	95,881,000	0	0	0	153,191,000	0	0	0	134,710,000	0	0	0	72,211,000	0	0	0	85,452,000	0	0	0	96,473,000	0	0	0	91,499,000	0	0	0	168,733,000	0	0	0	193,598,000	0	0	0	96,907,000	0	0	0	185,798,000	0	0	0	27,361,000			0	71,516,000		0	0	18,016,000
cash and cash equivalents at end of period								-35,063,000	75,639,000	-42,740,000	30,513,000	-2,722,000	110,830,000	-27,647,000	-29,620,000	108,177,000	102,281,000	-13,889,000	82,842,000	-23,746,000	89,503,000	35,917,000	14,682,000	-12,918,000	34,530,000	20,785,000	-46,448,000	-96,135,000	207,250,000	52,755,000	-36,663,000	-19,562,000	99,943,000	-8,863,000	-30,168,000	-522,000	131,052,000	24,087,000	-11,369,000	-18,958,000	174,973,000	-18,546,000	-9,073,000	-126,975,000	348,192,000	-21,351,000	-15,752,000	-22,386,000	156,396,000	29,964,000	36,773,000	-62,535,000	181,596,000		-14,743,000	-8,947,000	47,118,000		8,386,000	-9,030,000	47,879,000
adjustments to reconcile net income to net cash from operating activities:
non-cash revenue from the transfer of intellectual property																		0
loss on conversion of the 2025 notes																		0	0
gain on sale of genedx														-3,194,000	0
redemption of 2033 senior notes										0	0	0	-3,000,000													0	0	0	-28,800,000
net increase in cash and cash equivalents										-42,740,000	30,513,000			-27,647,000	-29,620,000	108,177,000	-32,429,000	-13,889,000			17,292,000			-12,918,000	-50,922,000	20,785,000	-46,448,000						8,444,000					24,087,000	-11,369,000	-18,958,000	-18,625,000	-18,546,000	-9,073,000	-126,975,000	251,285,000	-21,351,000	-15,752,000	-22,386,000	-29,402,000	29,964,000	36,773,000	-62,535,000	154,235,000	3,933,000	-14,743,000	-8,947,000	-24,398,000		8,386,000	-9,030,000	29,863,000
2025 convertible notes																			0
proceeds from sale of genedx															0
acquisition of businesses, net of cash															2,299,000																												15,812,000			0	12,000	-1,495,000	-200,000		20,450,000	0	78,000	-8,580,000	-8,339,000			-17,648,000	0	0	-10,538,000
fair value of shares received included in consideration from genedx holdings
issuance of common stock
net income														-85,231,000	-86,091,000	-101,650,000	-55,433,000	-73,774,000	28,739,000	-16,186,000	31,078,000																																							-5,746,000	-5,704,000
fair value of shares included in consideration from sema4															0
net cash from used in investing activities																	-4,903,000
proceeds from the exercise of common stock options and warrants																	136,000	201,000	413,000	158,000	308,000	87,000				0	0	0	-3,000	0	855,000			216,000	0	50,000	1,866,000	2,464,000	4,200,000	-242,000	2,154,000	741,000	7,814,000	4,654,000	12,712,000	862,000	9,319,000	1,108,000	1,639,000	18,364,000	3,542,000	524,000	995,000	577,000
asset impairment charges
issuance of 2023 convertible notes, including to related parties
operating lease right-of-use assets due to adoption of asu no. 2016-02																										3,554,000	6,186,000	-3,637,000	33,277,000
operating lease liabilities due to adoption of asu no. 2016-02																										3,464,000	6,190,000	-3,695,000	33,744,000
realized loss on disposal of fixed assets and sales of equity securities and other
change in fair value of equity securities and derivative instruments and other
impairment of assets																											0	0	655,000
issuance of convertible notes, including to related parties																											0	0	200,293,000
issuance of capital stock to acquire or contingent consideration settlement:
opko health europe																																		0	0			0	0	0	313,000	0	0
loss on disposal of fixed assets																												-64,000	284,000				-261,000
loss on conversion of 3.00% convertible senior notes																																											-1,234,000	-30,000	321,000					0
acquisition of intangible assets																																						0				0
maturities of short-term marketable securities																																						0												25,011,000				14,997,000					45,000,000
2033 senior notes																																										0	28,127,000	12,284,000	79,888,000	0	0
transition therapeutics, inc.																																						0
opko renal																																						0				0				0
issuance of stock for investment in xenetic																																						0
gain on disposal of fixed assets																															529,000
issuance of 2033 senior notes, including to related parties																															0
issuance of capital stock for contingent consideration settlement:
issuance of 2033 senior notes, net, including related parties																																	55,000,000
revenue from receipt of equity																																										0	-20,000	-60,000	-60,000	-60,000	-60,000	-60,000	-60,000	-60,000	-60,000	-80,000	-12,540,000			-51,000	-51,000
realized loss on equity securities and disposal of fixed assets																																		-5,980,000	-210,000	524,000	-2,997,000	1,378,000
change in fair value of derivative instruments																																		1,917,000	7,550,000	-5,482,000	-4,037,000	-8,667,000	5,701,000	-1,235,000	1,423,000	4,983,000	-32,244,000	16,556,000	49,788,000	14,390,000
gain on deconsolidation of scivac																																										1,400,000
deferred revenue																																		-18,514,000	-8,124,000	-16,661,000	-17,357,000	-17,913,000	-20,318,000	-18,129,000	-17,809,000	-18,591,000	-17,664,000	-18,312,000	282,238,000
cash from non-controlling interest																																										0	0	-691,000	791,000
bioreference laboratories, inc.
eirgen pharma limited																																										0	0
income taxes paid																																			1,578,000	3,473,000	848,000	-35,167,000	873,000	5,667,000	1,505,000	3,496,000	626,000	530,000	227,000	388,000	-230,000												8,000
in-process research and development																																														2,000,000	0
contingent consideration payments																																														0	0
pharmsynthez common stock received																																														0	0	0	6,264,000
bio-reference laboratories, inc.																																										138,000
opko uruguay ltda.
inspiro																																														0	0
realized gain on equity securities
realized gain on sale of equity securities																																											0	0	-216,000	1,440,000	1,000	-1,000	-1,273,000	-18,928,000
prepaid expenses and other current assets																																									-6,883,000	-166,000	-5,367,000	198,000	944,000	-305,000	163,000	2,179,000	1,145,000	950,000	491,000	-2,000	-2,570,000	-1,565,000	6,000	-837,000	-481,000	-167,000	317,000	286,000	-379,000
effect of exchange rate on cash and cash equivalents																																									590,000	-1,087,000	422,000	505,000	-957,000	80,000	-265,000	81,000	4,000	104,000	140,000	-94,000	-12,000
non-cash interest on 2033 senior notes																																										436,000	495,000	625,000	1,056,000	1,066,000	1,039,000	1,780,000	1,777,000
provision for bad debts
provision for inventory obsolescence																																										243,000	-27,000	490,000	220,000	309,000	190,000	246,000	337,000	486,000	256,000	334,000	939,000
gain on conversion of 3.00% convertible senior notes																																														0	0
loss on sale of property, plant and equipment																																																		4,000
payment of series d dividends, including related parties																																																		0	0	0	-3,015,000
rxi common stock received																																																			0	0	12,500,000
assets acquired under capital leases
series d preferred stock																																																			0	0	24,386,000
opko biologics
opko brazil																																																			0
(recovery of) provision for bad debts																																											7,682,000	452,000	174,000	666,000	48,000
deferred income tax expense
issuance of capital stock to acquire:
accrued expenses																																														6,600,000	1,997,000	4,344,000	-8,007,000	-6,149,000	2,337,000	5,031,000	-440,000	1,902,000	546,000	-1,340,000	1,253,000	-1,264,000	1,755,000	-649,000	-254,000
opko lab
issuance of common stock to acquire:
arama uruguay																																															0	0	159,000
change in fair value of derivatives instruments																																																-10,967,000	10,515,000	-2,202,000	27,793,000	-12,651,000	23,549,000
common stock options and warrants, net exercised																																																2,836,000	657,000
provision for (recovery of) bad debts																																																	-74,000			-52,000	381,000
income from discontinued operations, net of tax
non-cash interest on convertible senior notes																																																		1,730,000	1,130,000	1,817,000	1,303,000
changes in assets and liabilities of continuing operations, net of the effects of acquisitions:
cash from operating activities of continuing operations																																																		-26,050,000	-11,472,000	-5,925,000	-14,745,000		-2,023,000	-6,104,000	-11,574,000
cash from operating activities of discontinued operations																																																							96,000	-157,000	75,000
cash provided (or used) by investing activities from continuing operations
cash from investing activities from discontinued operations
net cash provided (or used) in investing activities
issuance of 3.00% convertible senior notes, net, including related parties																																																		0	0
issuance of common stock, net (including related parties) net
purchase of common stock held in treasury																																																										0	0
redemption of series a preferred stock (including related parties
changes in assets and liabilities of continuing operations, net of theeffects of acquisitions:
3.00% convertible senior notes
common stock warrants, net exercised																																																			0	0	815,000
issuance of common stock, common stock options and warrants to acquire prolor
cytochroma																																																			0	0	146,902,000
farmadiet
realized gain on investments available for sale																																																				-8,474,000	-2,347,000
proceeds from sale of investments available for sale																																																				8,968,000	2,528,000
repayments of lines of credit and capital lease obligations																																																				-10,767,000	-6,951,000
supplemental information
cash flows from operating activities
cash provided in operating activities of discontinued operations
income taxes refunded																																																					-118,000			203,000	-6,000
silcon																																																					436,000
accretion of debt discount related to notes payable																																																										0	0	0	2,000
equity based compensation – employees and non-employees
provision for (recovery of) inventory obsolescence
unrealized gains on derivative instruments																																																						-31,000
cash from operating activities from continuing operations																																																										-6,307,000
cash from operating activities from discontinued operations
cash from investing activities from continuing operations																																																										21,827,000
issuance of common stock, including related parties																																																										0	0	0	104,828,000
redemption of series a preferred stock including related parties
payment of series d dividends, including to related parties
repayments of line of credit with related party
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
loss from discontinued operations, net of tax
equity-based compensation - employees and non-employees																																																							1,112,000
loss from investments in investees																																																							468,000	473,000	523,000
provision for bad debt
revenue from receipt of equity in neovasc
redemption of series a preferred stock																																																											0
borrowings under lines of credit																																																											4,304,000
repayments under lines of credit																																																							-9,820,000	-10,798,000	-5,490,000		-4,916,000	-3,018,000	-2,827,000
cash and cash equivalents at beginning period
non-cash financing activities:
issuance of common stock to acquire farmadiet
(recovery of) provision for bad debt																																																								60,000	-151,000
provision for inventory reserves																																																								499,000	255,000
unrealized gain on investments, available for sale
contingent consideration																																																								965,000	1,144,000
borrowing under lines of credit																																																								11,216,000	10,337,000				3,027,000
proceeds from the exercise of stock options and warrants																																																								1,461,000	31,000	470,000	466,000	173,000	135,000
unrealized gain from warrants																																																									-1,117,000
cash flows from investing activities
write-off of acquired in-process research and development
benefit from (recovery of) bad debts
benefit from (recovery of) inventory obsolescence
foreign currency remeasurement
acquisition of rolapitant
maturities of marketable securities
issuance of series d preferred stock and warrants, including related parties
proceeds from bridge loan with related party
repayment of bridge loan with related party
net change in cash and cash equivalents
loss from continuing operations
provision for (recovery of) bad debt
changes in:
cash from operating activities from discontinuing operations
investment in neovasc
repayment of line of credit with related party
issuance of capital stock to acquire exakta-opko
equity-based compensation — employees and non-employees																																																												1,744,000	1,754,000
income from investments in investees																																																												451,000	423,000
benefit from bad debt
benefit from (reversal of) inventory reserves																																																												294,000	62,000
benefit from (recovery of) bad debt																																																													28,000
cash flows from investing activity
net cash from investing activity																																																													-70,629,000
repayments of notes payable and capital lease obligations
impairment of goodwill
equity based compensation — employees and non-employees
foreign exchange
loss on disposal of assets
license of product for equity
issuance of common stock for cash to related party
insurance financing and borrowings on lines of credit

OPKO Health, Inc(NASDAQ:OPK)

OPKO Health, Inc
(NASDAQ:OPK)